DIAGNOS Launches its New CARA (Computer Aided Retinal Analysis) Application and Signs the First Canadian Reseller for Ontario

DIAGNOS inc. ("DIAGNOS" or the "Corporation") (TSX VENTURE: ADK), a leader in the use of artificial intelligence ("AI") and advanced knowledge extraction techniques, launches CARA (Computer Aided Retinal Analysis) application bringing to market an 18 month development effort. CARA is an automated system for the identification of diabetic retinopathy and other eye related pathologies.

"I am very pleased to announce this new development based on our Artificial Intelligence platform. The software will be used for screening patients in hospitals, as well as private and public clinics and practices. The World Health Organization estimates that by year 2030, 366,000,000 people will have diabetes.

DIAGNOS' goal is to provide our open platform analysis tool, to expand the diagnostic capabilities of more than 200,000 digital retinal imaging systems which currently exist worldwide. Our strategy is to establish a network of resellers that specifically sells to existing hospitals, clinics and optometrists today. We will be sharing revenues based on a split of 25% to our resellers and 75% to DIAGNOS" said Andre Larente, Chairman and CEO of DIAGNOS.

Reid Hayes, President of BH Optical stated: "We are very proud to be chosen as the first exclusive reseller of this application covering our largest single market, Ontario, Canada. For over 28 years, BH Optical has been servicing approximately 3,000 customers in Canada of which 1,500 are based in Ontario. Our objective is to sign on 100 clients within the next 12 months and we expect to receive 100 patient retinal images per week per client with a total expectation of 450,000 images in the first year of deployment. Our pricing strategy will be to charge $10 as a fixed fee per patient. The DIAGNOS system will definitely extend the range and capability of interpreting digital images and it has the potential of assisting in the early detection of many other pathologies as well. We expect to have our first diabetic clinic using the system within 60 days."

DIAGNOS can count on a multidisciplinary team that includes professionals in Artificial Intelligence, mathematics, business intelligence as well as image interpretation. One of the Corporation's objectives is to develop a royalty stream by significantly enhancing existing imaging infrastructure such as in the health care market. For further information, please visit our Website at www.diagnos.ca.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contacts: DIAGNOS Inc. Andre Larente Chairman and CEO 450-678-8882, ext. 224 This email address is being protected from spambots. You need JavaScript enabled to view it. DIAGNOS Inc. Daniel Courtney Director of Investor Relations 807-768-9112 This email address is being protected from spambots. You need JavaScript enabled to view it.

SOURCE: DIAGNOS Inc.

mailto:This email address is being protected from spambots. You need JavaScript enabled to view it. mailto:This email address is being protected from spambots. You need JavaScript enabled to view it.